Evidence map›Paper›PMID 33176870›Full record

Trial reportTrials2020

Effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine: a single-centre, randomised, double-blind, sham-controlled phase 2 trial (Magnet-EM).

Nabil Izzaatie Mohamad Safiai, Nur Ain Amir, Hamidon Basri, Liyana Najwa Inche Mat, Fan Kee Hoo, Abdul Hanif Khan Yusof Khan, Wei Chao Loh, Peck Kee Chia, Vasudevan Ramachandran, Hazwan Mat Din and 6 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03556722 (Effectiveness and Tolerability of Repetitive Transcranial Magnetic Stimulation For Preventive Treatment Of Episodic Migraine), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03556722 nacompletednot on this map

Effectiveness and Tolerability of Repetitive Transcranial Magnetic Stimulation For Preventive Treatment Of Episodic Migraine: A Single Centre, Randomised, Double-Blind, Sham-Controlled Phase 2 Trial

TypeinterventionalSponsorUniversiti Putra MalaysiaRan2019 to 2022Enrolled76ConditionsMigraineArmsRepetitive Transcranial Magnetic Stimulation., Sham rTMS
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Nabil Izzaatie Mohamad SafiaiDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Nur Ain AmirDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Hamidon BasriDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Liyana Najwa Inche MatDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Fan Kee HooDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Abdul Hanif Khan Yusof KhanDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Wei Chao LohDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Peck Kee ChiaDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Vasudevan RamachandranMalaysian Research Institute on Ageing, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Hazwan Mat DinMalaysian Research Institute on Ageing, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Intan Nureslyna SamsudinDepartment of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Aaron FernandezDepartment of Psychiatry, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Mohd Hazmi MohamedDepartment of ORL-HNS, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Siew Mooi ChingDepartment of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia.
Hasnur Zaman HashimNeurology services, Columbia Asia Hospital-Klang, Jalan Mahkota 1/ KU2, Mutiara Bukit Raja 2, 41050, Klang, Selangor, Malaysia.
Wan Aliaa Wan SulaimanDepartment of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400, Serdang, Selangor, Malaysia. wanaliaa@upm.edu.my.ORCID http://orcid.org/0000-0003-4969-0308
Universiti Putra Malaysia · MY

Funding

Universiti Putra Malaysia GPB/2017/9585500
6 · The paper itself

Abstract

backgroundThis is a phase II randomised, double-blind, sham-controlled trial to evaluate the effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine amongst migraine subjects.

methodsSubjects age 18 to 60 years will undergo a baseline evaluation to establish the diagnosis of migraine based on the International Classification of Headache Disorder 3rd Edition (ICHD-3). Those who fulfil the ICHD-3 criteria for episodic migraine and compliant to the headache diary during a month run-in period will be enrolled. A total of 76 subjects will be randomised to receive either transcranial magnetic stimulation or sham stimulation for 5 sessions within 2 weeks duration. Follow-up sessions will be conducted monthly for three consecutive months. Prior to treatment, subjects will be required to fill up questionnaires and undergo few procedures such as electroencephalography, transcranial Doppler ultrasound and biochemical analysis for serum serotonin, serum calcitonin gene-related peptide and serum beta-endorphin. These procedures will be repeated at month 3 after receiving the last treatment. The primary outcome measure of this study is the difference in mean monthly migraine days at baseline and at months 1, 2 and 3 after treatment sessions. DISCUSSION: Following evidence from previous studies showing restoration of dorsolateral prefrontal cortex (DLPFC) activation to almost normal level, the rTMS intervention will target left DLPFC in this study. An intermediate duration of treatment sessions is selected for this study. It is set to five treatment sessions given within 2 weeks duration.

trial registrationClinicalTrials.gov NCT03556722 . Registered on 14 June 2018.

Indexed as

Migraine DisordersTranscranial Magnetic StimulationAdolescentAdultDouble-Blind MethodHumansMagnetsMiddle AgedTreatment OutcomeYoung AdultMigraineRandomised controlled trialRepetitive transcranial magnetic stimulation (TMS)

Identifiers

PMID33176870
PMCPMC7657359
OpenAlexW3099643272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.